BCYC
Price
$8.19
Change
+$0.41 (+5.27%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
538.8M
84 days until earnings call
PHIO
Price
$1.81
Change
-$0.23 (-11.27%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
8.6M
Ad is loading...

BCYC vs PHIO

Header iconBCYC vs PHIO Comparison
Open Charts BCYC vs PHIOBanner chart's image
Bicycle Therapeutics
Price$8.19
Change+$0.41 (+5.27%)
Volume$5.64K
Capitalization538.8M
Phio Pharmaceuticals
Price$1.81
Change-$0.23 (-11.27%)
Volume$224
Capitalization8.6M
BCYC vs PHIO Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. PHIO commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and PHIO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (BCYC: $7.78 vs. PHIO: $2.04)
Brand notoriety: BCYC and PHIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 170% vs. PHIO: 278%
Market capitalization -- BCYC: $538.8M vs. PHIO: $8.6M
BCYC [@Biotechnology] is valued at $538.8M. PHIO’s [@Biotechnology] market capitalization is $8.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whilePHIO’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • PHIO’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while PHIO’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 6 bearish.
  • PHIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PHIO is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -9.11% price change this week, while PHIO (@Biotechnology) price change was +6.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

PHIO is expected to report earnings on Mar 31, 2025.

Industries' Descriptions

@Biotechnology (-3.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($539M) has a higher market cap than PHIO($8.6M). PHIO YTD gains are higher at: 13.333 vs. BCYC (-44.429). PHIO has higher annual earnings (EBITDA): -7.41M vs. BCYC (-164.89M). BCYC has more cash in the bank: 880M vs. PHIO (5.39M). PHIO has less debt than BCYC: PHIO (0) vs BCYC (9.49M). BCYC has higher revenues than PHIO: BCYC (35.3M) vs PHIO (0).
BCYCPHIOBCYC / PHIO
Capitalization539M8.6M6,267%
EBITDA-164.89M-7.41M2,226%
Gain YTD-44.42913.333-333%
P/E RatioN/A0.01-
Revenue35.3M0-
Total Cash880M5.39M16,327%
Total Debt9.49M0-
FUNDAMENTALS RATINGS
BCYC vs PHIO: Fundamental Ratings
BCYC
PHIO
OUTLOOK RATING
1..100
1694
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8695
PRICE GROWTH RATING
1..100
6548
P/E GROWTH RATING
1..100
10060
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (24) in the null industry is somewhat better than the same rating for PHIO (65) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than PHIO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as PHIO (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

BCYC's SMR Rating (86) in the null industry is in the same range as PHIO (95) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's Price Growth Rating (48) in the Biotechnology industry is in the same range as BCYC (65) in the null industry. This means that PHIO’s stock grew similarly to BCYC’s over the last 12 months.

PHIO's P/E Growth Rating (60) in the Biotechnology industry is somewhat better than the same rating for BCYC (100) in the null industry. This means that PHIO’s stock grew somewhat faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCPHIO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZBRA257.286.43
+2.56%
Zebra Technologies Corp
FBP20.120.11
+0.55%
First BanCorp
HSCS3.460.01
+0.29%
HeartSciences Inc
OFLX30.370.03
+0.10%
Omega Flex
MRCC6.92-0.06
-0.86%
Monroe Capital Corp

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+5.14%
INO - BCYC
54%
Loosely correlated
+2.92%
XNCR - BCYC
53%
Loosely correlated
-5.61%
RPTX - BCYC
51%
Loosely correlated
+2.26%
RLAY - BCYC
48%
Loosely correlated
-6.35%
RCKT - BCYC
46%
Loosely correlated
+6.18%
More

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with MTNB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
+18.60%
MTNB - PHIO
50%
Loosely correlated
+11.39%
TPST - PHIO
49%
Loosely correlated
-3.75%
SAGE - PHIO
40%
Loosely correlated
-0.58%
IMNN - PHIO
39%
Loosely correlated
-1.22%
BPMC - PHIO
39%
Loosely correlated
+0.65%
More